Clinical trials: Bird Flu
Pandemic Influenza
A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza
This aim of this project is to evaluate the efficacy of neuraminidase inhibitors as short-term prophylaxis against pandemic influenza infection in people who have close familial contact with the disease.
- Trial name
- PIPET C (NCT00640874)
- Where
- 8 sites in Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Kirby Institute
Influenza, Human
A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
The aim of this study is to evaluate the safety, reactogenicity and immunogenicity of the Flu Pandemic messenger RNA (mRNA) vaccine (including dose-finding and dose-confirmation) administered in healthy adults 18 to 85 years of…
- Trial name
- NCT06382311
- Testing
- Flu Pandemic mRNA_Dose level 1, Flu Pandemic mRNA_Dose level 2, Flu Pandemic mRNA_ Dose level 3.
- Where
- 21 sites in United States
- Volunteers
- 991 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pandemic Influenza, Influenza A Virus Infection
Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults
The purpose of this study is to test different adjuvanted vaccine formulations as a two-dose schedule in immunologically naïve adults against one vaccine formulation without adjuvant in terms of tolerance and immunogenicity…
- Conditions
- Pandemic Influenza, Influenza A Virus Infection, Orthomyxoviridae Infections
- Trial name
- NCT00457509
- Testing
- A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant, A/H5N1 inactivated, split-virion influenza vaccine
- Where
- 3 sites in Belgium
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
Panblok H7 Vaccine Adjuvanted With AS03 or MF59
The main purpose of this study is to assess the safety and ability of a Panblok H7 influenza vaccine adjuvanted with AS03 or MF59 to generate an immune response after 2 doses separated by 28 days.
- Trial name
- NCT03283319
- Testing
- 3.75 ug Panblok H7, 7.5 ug Panblok H7, 15 ug Panblok H7
- Where
- 4 sites in United States
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Biomedical Advanced Research and Development Authority
Bird Flu, Avian Influenza
A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine
The focus of this study is to evaluate the safety, reactogenicity and humoral immune responses of the study vaccine when administered at the dose of 7.5 µg HA, 15 µg HA, or 30 µg HA to human subjects.
- Conditions
- Bird Flu, Avian Influenza, Influenza A(H5N1)
- Trial name
- NCT01675284
- Testing
- AT-301
- Where
- Taiwan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Medigen Biotechnology Corporation
Influenza
Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects
This study is designed to evaluate the immunogenicity, safety and tolerability of 2 doses of FLUAD-H5N1 vaccine compared to 2 doses of trivalent, interpandemic FLUAD, each administered 3 weeks apart.
- Trial name
- NCT00434733
- Testing
- Pandemic influenza vaccine
- Where
- Poland
- Volunteers
- 4,400 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza, Pandemic Influenza
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
The objectives of this study are to assess the dose-related safety and immunogenicity of six different dose levels of inactivated, Vero cell-derived reverse genetic reassortant A/H5N1/Indonesia/05/2005 influenza vaccine in a…
- Trial name
- NCT00783926
- Testing
- H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)
- Where
- 6 sites in United States
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Higher Dose Intradermal H5 Vaccine
This study will compare the influenza A/H5N1 virus vaccine given by injection in the muscle versus injection in the skin in healthy adults.
- Trial name
- NCT00439335
- Testing
- Inactivated Influenza A Vaccine A/H5N1
- Where
- United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Avian Influenza, Influenza
H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults
This is a Phase I randomized, double-blind, controlled trial in 275 males and non-pregnant females, 19 to 64 years old, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT02624219
- Testing
- AS03, MF59 adjuvant, Monovalent Influenza A/H5N8 vaccine
- Where
- 4 sites in United States
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
T and B Cell Response to Avian Flu Vaccine
The purpose of this substudy study is to evaluate the types of cells involved in fighting infection to the A/H5N1 (avian flu virus) vaccine.
- Trial name
- NCT00337896
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza (Pandemic)
A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1
The purpose of this study is to evaluate the immunogenicity and safety profile of the Avian flu vaccine with and without adjuvant 1 in healthy, young adults. The study is divided down into Parts A1, A2 and B.
- Trial name
- NCT01594320
- Testing
- Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant
- Where
- 5 sites in United States
- Volunteers
- 333 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza
Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49
The purpose of this study is to test an investigational vaccine known as "VAX161C." An "investigational" vaccine is one that is not licensed for commercial use in the by the United States (US) by the US Food and Drug…
- Trial name
- NCT01658800
- Testing
- VAX161C vaccine
- Where
- 2 sites in United States
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
Influenza
A/H5N1 Vaccine in Healthy Children Aged 2-9 Years
The purposes of this study are: to make sure that there are no serious side effects of an experimental inactivated influenza A/H5N1 vaccine in children; and to see how the body's immune system reacts to the vaccine.
- Trial name
- NCT00133536
- Testing
- Influenza A/H5N1 Vaccine
- Where
- 4 sites in United States
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Prospective Study of AI H5N1 in China
The purpose of this study is to see if people in China who have contact with someone infected with bird flu (H5N1) become infected themselves without necessarily getting sick.
- Trial name
- NCT00428493
- Where
- China
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Preventive Avian Flu
Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers
The purpose of this study is to evaluate safety and reactogenicity of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) manufactured by GPO, in Thailand to previously healthy Thais.
- Trial name
- NCT01656356
- Testing
- Avian Flu Vaccine
- Where
- Thailand
- Volunteers
- healthy volunteers welcome
- Sponsor
- Mahidol University
Avian Influenza
A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age
This Phase 3 study evaluates the safety, immunogenicity and lot-to lot consistency of 3 lots of aH5N1c vaccine for pandemic avian influenza, in approximately 2394 healthy adults ≥18 years of age receiving the vaccine and 797…
- Trial name
- NCT02839330
- Testing
- aH5N1c
- Where
- 26 sites in United States
- Volunteers
- 3,196 people, healthy volunteers welcome
- Sponsor
- Seqirus
Pandemic Influenza
Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults
The objectives of this single arm study are to evaluate the immune response and safety profiles of two injections of an inactivated whole-virion vaccine containing aluminum hydroxide adjuvant, AdimFlu-W (H5N1), against influenza…
- Trial name
- NCT01640691
- Testing
- Pandemic Influenza Vaccine (H5N1)
- Where
- Taiwan
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Avian Influenza, Immunisation
A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine
A phase I prospective, randomized study in healthy adult subjects at a single center. Adult subjects age 18 to 47 years and meeting all enrollment criteria will choose to participate as subjects who receive inactivated vaccine…
- Trial name
- NCT02251288
- Testing
- Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, MF59 adjuvant
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
H5N1 Mix and Match With MF59
Approximately 216, and up to 270, healthy males and non-pregnant females, 18 to 49 years old, inclusive, will be enrolled over a 5-month period into this multicenter, randomized, double-blinded, controlled Phase I study.
- Trial name
- NCT01317745
- Testing
- Phosphate Buffered Saline (PBS) diluent, MF59 Adjuvant, H5N1 Antigen
- Where
- 5 sites in United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Avian Influenza
Immunogenicity of ND1.1 by Delivery Directly to the Ileum
The purpose of the study is to determine the safety and tolerability of ND1.1, an adjuvanted adenoviral-based avian influenza vaccine, when delivery is targeted to the ileum, using a radio controlled capsule.
- Trial name
- ICC H5 (NCT01698060)
- Testing
- ND1.1
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Vaxart